Disease-modifying medications in heart failure: more than ACE inhibitors and beta blockers by Ter Chao, Chia
LETTER TO THE EDITOR
Disease-modifying medications in heart failure: more
than ACE inhibitors and beta blockers
Chia-Ter Chao
Division of Nephrology, Department of Internal Medicine, National Taiwan University Hospital, College of Medicine, National Taiwan University, Taipei,
Taiwan.
Email: b88401084@ntu.edu.tw.
Tel.: 886-2-23123456
To the editor,
I read with great interest the article entitled ‘‘Predictors of
low cardiac output in decompensated severe heart failure’’
by Ochiai et al1 in the Feb. 2011 issue of Clinics. This article
analyzes factors predicting low cardiac output and mortal-
ity in systolic heart failure patients presenting with poor
perfusion signs. Though the study design and findings are
intriguing, I think there are some points that the authors
may have missed.
First, the authors define compromised perfusion a priori
as a combination of narrow pulse pressure, symptomatic
hypotension, cool extremities, and impaired mental func-
tion. However, decreased urine output seems to be omitted
as part of the presentation. Systemic hypoperfusion, by
itself, can disrupt the way that vital organs work, and the
brain and the kidney are both targets whose performance
can be assessed at the bedside. Physiologic studies also
demonstrate that blood pressure changes through variation
in renal medullary perfusion2 and proximal tubular sodium
transport3 affect urine output level in the same direction.4
Thus, it is my opinion that decreased urine output should be
listed as a sign of hypoperfusion.
In addition, Ochiai et al have elegantly shown the effect of
medication on mortality, including the protective roles of
angiotensin-converting enzyme inhibitors (ACEi) and beta-
blockers (BB). However, while adjusting the variables in
determining predictors of low cardiac output (CO), they seem
to neglect this medication factor. In the long run, both BB and
ACEi are beneficial for patients with systolic heart failure, but
each also has a short-term hemodynamic effect, as BB causes
negative inotropic effects while ACEi reduces peripheral
vascular tone.5 These effects will also influence the CO status
if the distribution of these medications is imbalanced between
groups. BB users will have a higher chance of being grouped
into the lower CO category, while ACEi users have a higher
chance of being grouped into the higher CO category because
of the decreased likelihood of creatinine clearance ,60 ml/
min stratum (if physicians prescribe less ACEi in patients with
advanced chronic kidney disease).
The authors also fail to report the percentage of digitalis
usage in the population. Since the early 20th century,
digoxin has been utilized in patients with systolic heart
failure to improve symptoms and to reduce rates of
hospitalization.6 Though digoxin is shown to be neutral
for overall mortality in pooled systolic heart failure
patients, a higher serum digoxin concentration is asso-
ciated with increased all-cause mortality.7 In light of the
elderly population described by Ochiai et al (average .60
years old) and the erratic pharmacokinetic profile of old
patients using digoxin,8 it is likely that elderly individuals
who suffer from systolic heart failure will have a higher
serum digoxin concentration if given digoxin. This
contribution to overall mortality cannot be treated in the
same way as in previous meta-analyses that focus on all
digoxin users. Ahmed et al, in a post hoc analysis of the
Digitalis Investigation Group (DIG) results, suggest that
targeting lower serum digoxin concentration in all
patients with a reduced left ventricular ejection fraction
can reduce mortality.9 The effect of digoxin and Chagas’
cardiomyopathy, both of which may slow the heart rate
because of an atrioventricular block, further complicates
the clinical picture in heart failure patients.10 Thus, the
importance of reporting digoxin usage or even checking
the serum concentration cannot be overemphasized in this
context.
In conclusion, there are several aspects, most impor-
tantly the medication regimen for heart failure, that should
be clarified in the article by Ochiai et al. The study results
can only be refined further if these confounders are
considered.
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